Percutaneous Closure of Iatrogenic VSD and Paravalvular Leak: Two Complications of TAVR

Shazib Sagheer; Shane Prejean; Thomas Watts; Mark A Law; Mustafa Iltimas Ahmed

doi:10.1016/j.carrev.2021.03.015

Percutaneous Closure of Iatrogenic VSD and Paravalvular Leak: Two Complications of TAVR

Cardiovasc Revasc Med. 2021 Jul:28S:75-77. doi: 10.1016/j.carrev.2021.03.015. Epub 2021 Mar 23.

Authors

Shazib Sagheer¹, Shane Prejean², Thomas Watts², Mark A Law³, Mustafa Iltimas Ahmed⁴

Affiliations

¹ University of New Mexico Health Sciences Center, United States of America. Electronic address: [email protected].
² University of Alabama at Birmingham Hospital, AL, United States of America.
³ Division of Interventional Cardiology, University of Alabama at Birmingham Hospital, AL, United States of America.
⁴ Division of Pediatric Interventional Cardiology, University of Alabama at Birmingham Hospital, AL, United States of America.

PMID: 33773926
DOI: 10.1016/j.carrev.2021.03.015

Abstract

TAVR is increasingly becoming a common treatment for severe symptomatic aortic stenosis. Although there has been marked reduction in intra-procedural complications with evolution in the TAVR technology, these complications remain a challenge. We present a unique case of paravalvular leak (PVL) and iatrogenic ventricular septal defect as a result of closing attempts of PVL. We aim to highlight our procedural approach to percutaneously repair the aforementioned complications using our heart team approach for decision making.

Keywords: AMplatzer AVP II; Iatrognenic VSD; Paravalvular leak; TAVR; muscular VSD occluder.

Publication types

Case Reports

MeSH terms

Cardiac Catheterization / adverse effects
Heart Septal Defects, Ventricular* / diagnostic imaging
Heart Septal Defects, Ventricular* / surgery
Heart Valve Prosthesis Implantation* / adverse effects
Heart Valve Prosthesis*
Humans
Iatrogenic Disease
Septal Occluder Device*
Transcatheter Aortic Valve Replacement* / adverse effects
Treatment Outcome